Ask AI
Log In Sign Up
Go to General VC Questions
Previous Question
Next Question
1
General VC Questions
Sideletters Healthtech Biotech

I can't confidently answer this question, please start a new Decile Base post to have this question answered.

Asked by: Shaaf Farooq
0
0
Mar 16, 2025
The new SEC rules limit preferential treatment in Side Letters (Section 8.3). Historically, institutional LPs negotiated preferential terms via Side Letters, so I want to know if they’re now pushing back or finding workarounds. I also want to understand how biotech/health funds are handling regulatory carve-outs that LPs previously included in Side Letters.

Log In or Sign Up

Please Log In, or Sign Up to participate in the discussion.

Log In
or
Sign Up

Apply to VC Lab Cohort 18

Get full access to Decile Base and the Decile Hub venture platform for free by joining the VC Lab program.

Apply to VC Lab Cohort 18
Related Questions
Quick question: Does leading a deal infers dropping the largest check? 0 May 03, 2023 Should We Include Individual or Collective Track Records of the Fund Team in Question #4? 0 May 03, 2023 How to Respond to PitchBook Queries About My Investment Firm and Its Benefits After Fund Formation? 1 May 03, 2023 What is the difference between an SPV and a fund, and why can't we operate as an SPV structure? 0 May 03, 2023 What exactly is a 1099 reportable transaction? 1 Mar 16, 2025

Decile Group Inc. uses cookies for our website to function properly; some are optional and help deliver a personalized and enhanced experience. By clicking "Allow all", you consent to store cookies on your device in accordance with our cookie policy. You can reject all non-essential processing by choosing to accept only necessary cookies. To learn more check Cookie Policy